Literature DB >> 24610630

Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord.

Dhruv Sareen1, Geneviève Gowing, Anais Sahabian, Kevin Staggenborg, Renée Paradis, Pablo Avalos, Jessica Latter, Loren Ornelas, Leslie Garcia, Clive N Svendsen.   

Abstract

Transplantation of human neural progenitor cells (NPCs) into the brain or spinal cord to replace lost cells, modulate the injury environment, or create a permissive milieu to protect and regenerate host neurons is a promising therapeutic strategy for neurological diseases. Deriving NPCs from human fetal tissue is feasible, although problematic issues include limited sources and ethical concerns. Here we describe a new and abundant source of NPCs derived from human induced pluripotent stem cells (iPSCs). A novel chopping technique was used to transform adherent iPSCs into free-floating spheres that were easy to maintain and were expandable (EZ spheres) (Ebert et al. [2013] Stem Cell Res 10:417-427). These EZ spheres could be differentiated towards NPC spheres with a spinal cord phenotype using a combination of all-trans retinoic acid (RA) and epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2) mitogens. Suspension cultures of NPCs derived from human iPSCs or fetal tissue have similar characteristics, although they were not similar when grown as adherent cells. In addition, iPSC-derived NPCs (iNPCs) survived grafting into the spinal cord of athymic nude rats with no signs of overgrowth and with a very similar profile to human fetal-derived NPCs (fNPCs). These results suggest that human iNPCs behave like fNPCs and could thus be a valuable alternative for cellular regenerative therapies of neurological diseases.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Human iPS cells; neural progenitor cells; astrocytes; cell transplantation; regenerative therapy; ALS

Mesh:

Substances:

Year:  2014        PMID: 24610630      PMCID: PMC4070510          DOI: 10.1002/cne.23578

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  95 in total

1.  Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.

Authors:  Francesco Paolo Di Giorgio; Monica A Carrasco; Michelle C Siao; Tom Maniatis; Kevin Eggan
Journal:  Nat Neurosci       Date:  2007-04-15       Impact factor: 24.884

2.  Astrocytic complexity distinguishes the human brain.

Authors:  Nancy Ann Oberheim; Xiaohai Wang; Steven Goldman; Maiken Nedergaard
Journal:  Trends Neurosci       Date:  2006-08-30       Impact factor: 13.837

3.  Specification of motoneurons from human embryonic stem cells.

Authors:  Xue-Jun Li; Zhong-Wei Du; Ewa D Zarnowska; Matthew Pankratz; Lauren O Hansen; Robert A Pearce; Su-Chun Zhang
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

4.  Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients.

Authors:  Jonathan D Glass; Nicholas M Boulis; Karl Johe; Seward B Rutkove; Thais Federici; Meraida Polak; Crystal Kelly; Eva L Feldman
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

5.  Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease.

Authors:  C N Svendsen; M A Caldwell; J Shen; M G ter Borg; A E Rosser; P Tyers; S Karmiol; S B Dunnett
Journal:  Exp Neurol       Date:  1997-11       Impact factor: 5.330

6.  Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture.

Authors:  Yirui Sun; Steven Pollard; Luciano Conti; Mauro Toselli; Gerardo Biella; Georgina Parkin; Lionel Willatt; Anna Falk; Elena Cattaneo; Austin Smith
Journal:  Mol Cell Neurosci       Date:  2008-03-18       Impact factor: 4.314

7.  Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain.

Authors:  Martha S Windrem; Marta C Nunes; William K Rashbaum; Theodore H Schwartz; Robert A Goodman; Guy McKhann; Neeta S Roy; Steven A Goldman
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

Authors:  Ryoko Araki; Masahiro Uda; Yuko Hoki; Misato Sunayama; Miki Nakamura; Shunsuke Ando; Mayumi Sugiura; Hisashi Ideno; Akemi Shimada; Akira Nifuji; Masumi Abe
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

9.  A simple tool to improve pluripotent stem cell differentiation.

Authors:  Sundari Chetty; Felicia Walton Pagliuca; Christian Honore; Anastasie Kweudjeu; Alireza Rezania; Douglas A Melton
Journal:  Nat Methods       Date:  2013-04-14       Impact factor: 28.547

10.  Brain injury-associated biomarkers of TGF-beta1, S100B, GFAP, NF-L, tTG, AbetaPP, and tau were concomitantly enhanced and the UPS was impaired during acute brain injury caused by Toxocara canis in mice.

Authors:  Chien-Wei Liao; Chia-Kwung Fan; Ting-Chang Kao; Dar-Der Ji; Kua-Eyre Su; Yun-Ho Lin; Wen-Long Cho
Journal:  BMC Infect Dis       Date:  2008-06-24       Impact factor: 3.090

View more
  60 in total

Review 1.  Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.

Authors:  Kevin S Chen; Stacey A Sakowski; Eva L Feldman
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

Review 2.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

3.  Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening.

Authors:  Chialin Cheng; Daniel M Fass; Kat Folz-Donahue; Marcy E MacDonald; Stephen J Haggarty
Journal:  Curr Protoc Hum Genet       Date:  2017-01-11

4.  Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology.

Authors:  Ping-Wu Zhang; Amanda M Haidet-Phillips; Jacqueline T Pham; Youngjin Lee; Yuqing Huo; Pentti J Tienari; Nicholas J Maragakis; Rita Sattler; Jeffrey D Rothstein
Journal:  Glia       Date:  2015-08-21       Impact factor: 7.452

Review 5.  Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.

Authors:  Stephen A Goutman; Masha G Savelieff; Stacey A Sakowski; Eva L Feldman
Journal:  Expert Opin Investig Drugs       Date:  2019-06-12       Impact factor: 6.206

Review 6.  Modeling ALS and FTD with iPSC-derived neurons.

Authors:  Sebum Lee; Eric J Huang
Journal:  Brain Res       Date:  2015-10-14       Impact factor: 3.252

7.  Human iPSC-Derived Neural Progenitors Preserve Vision in an AMD-Like Model.

Authors:  Yuchun Tsai; Bin Lu; Benjamin Bakondi; Sergey Girman; Anais Sahabian; Dhruv Sareen; Clive N Svendsen; Shaomei Wang
Journal:  Stem Cells       Date:  2015-06-02       Impact factor: 6.277

8.  Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo.

Authors:  B E Hjelm; C Grunseich; G Gowing; P Avalos; J Tian; B C Shelley; M Mooney; K Narwani; Y Shi; C N Svendsen; J H Wolfe; K H Fischbeck; T M Pierson
Journal:  Gene Ther       Date:  2016-02-10       Impact factor: 5.250

9.  Glial restricted precursors maintain their permissive properties after long-term expansion but not following exposure to pro-inflammatory factors.

Authors:  Kazuo Hayakawa; Christopher Haas; Ying Jin; Julien Bouyer; Takanobu Otsuka; Itzhak Fischer
Journal:  Brain Res       Date:  2015-10-21       Impact factor: 3.252

10.  Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury.

Authors:  Ke Li; Elham Javed; Daniel Scura; Tamara J Hala; Suneil Seetharam; Aditi Falnikar; Jean-Philippe Richard; Ashley Chorath; Nicholas J Maragakis; Megan C Wright; Angelo C Lepore
Journal:  Exp Neurol       Date:  2015-07-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.